Huppy hump day, !

This week we dive into the Telemedicine market, with $35.8B in online consultations revenue by 2028.

AI-driven medtech is scaling fast, with surging FDA approvals, but regulatory and clinical hurdles remain key to sustained growth.

Healthcare M&A cools down sharply, with deal values down 29% YoY and a 72% plunge from the 2021 peak.

-Healthcare 150 Team

From Pandemic Necessity to Market Opportunity: The Business of Telemedicine

Telemedicine is no longer a fringe innovation, it's a fundamental shift in healthcare delivery, with online doctor consultations projected to reach 130.4 million users by 2028. The industry's rapid expansion highlights how digital solutions are addressing accessibility, efficiency, and convenience on a global scale. The financial trajectory is equally compelling, with market revenue soaring from $4.5 billion in 2017 to a projected $35.8 billion by 2028. Investors and healthcare executives are now looking at telemedicine as a mature, scalable industry rather than a temporary pandemic-driven trend. COVID-19 was the defining catalyst for digital healthcare, pushing telemedicine adoption from 16% to 80.5% among office-based physicians in just two years. This surge has permanently altered patient expectations, making virtual care an integral part of modern healthcare systems.

Leading states like Maryland, Connecticut, and Massachusetts are setting the standard for hospital-based telehealth adoption, with over 90% of hospitals now offering digital services. Strong policy support, funding incentives, and advanced healthcare ecosystems are accelerating widespread integration. Despite a post-pandemic decline in Medicare telehealth use—from 48% in 2020 to 24% in 2023—the sector is stabilizing into a long-term hybrid model. The opportunity now lies in refining patient engagement, expanding telehealth for chronic care, and integrating virtual visits into traditional healthcare systems. The next phase of telemedicine will focus on quality, personalization, and seamless digital experiences, making this a pivotal moment for investors and healthcare providers. As global demand continues to rise, those who innovate and scale effectively will define the future of digital healthcare.

Want to learn more?

You Drive the Future of Healthcare—Let’s Secure Yours.

As a healthcare finance leader or cardiologist, you navigate complex investments, high earnings, and strategic decisions daily. But is your personal wealth managed with the same level of expertise?

That’s where Range comes in.

Range is a modern, all-in-one wealth management platform built for high-income professionals in healthcare and finance. Their flat-fee, fiduciary model ensures tax optimization, equity planning, real estate strategy, and investment management—all aligned to maximize your financial future, without conflicts of interest.

Whether you’re structuring M&A deals in healthcare or managing a thriving medical career, your wealth deserves the same precision you bring to your profession.

Even if you already have an advisor, you’d be surprised how much more in fees you could save.

Ready to take a smarter approach to your financial health?

Book a complimentary demo and see how Range helps healthcare finance leaders and top physicians build lasting wealth.

Healthcare M&A: The Great Cooldown

The Global health M&A market is catching a cold. Deal volumes are down 20% YoY, while values plunged 29%. Pharma and life sciences took the biggest hit—fewer megadeals ($5B+) meant a 31% value drop. Healthcare services? Not immune, with deal volumes and values down 22% and 21%.

And let’s talk about the real gut punch: from the 1H21 peak, deal value has cratered 72% and Deal Volume 43%.

With capital tightening and fewer big bets, dealmakers are choosing caution over FOMO. Is this the new normal?

Premium Perks

Since you are an Executive Subscriber, you get access to all the full length reports our research team makes every week. Interested in learning all the hard data behind the article? If so, this report is just for you.

Want to check the other reports? Access the Report Repository here.

Health Tech Corner: AI-Driven MedTech is Scaling Fast

AI and machine learning in medical technology are no longer emerging trends—they are now a dominant force in healthcare innovation. FDA approvals for AI/ML-enabled medtech products have surged from just five in 2015 to 185 in 2023, reflecting the sector’s rapid adoption and regulatory acceptance. 

Despite this momentum, regulatory scrutiny and clinical validation remain critical hurdles for AI-driven solutions. While the FDA has accelerated approvals, the industry must address issues like data bias, interoperability, and patient safety to ensure continued growth. The sector’s ability to navigate these challenges will determine whether this exponential trajectory can be sustained in the coming years.

For investors, the opportunity lies in companies that balance innovation with regulatory rigor. With AI’s role in healthcare expanding, those developing clinically validated, scalable, and reimbursement-friendly solutions will capture the lion’s share of market growth. Expect continued investment in AI-powered diagnostics, robotic-assisted surgery, and predictive analytics as the industry pushes forward. ​

You Drive the Future of Healthcare—Let’s Secure Yours.

Range is a modern, all-in-one wealth management platform built for high-income professionals in healthcare and finance. Their flat-fee, fiduciary model ensures tax optimization, equity planning, real estate strategy, and investment management—all aligned to maximize your financial future, without conflicts of interest.

Ready to take a smarter approach to your financial health?

Book a complimentary demo and see how Range helps healthcare finance leaders and top physicians build lasting wealth.

Boston Scientific Drops $540M on Sonivie

Boston Scientific is adding another notch to its aggressive M&A streak, acquiring Sonivie for up to $540 million. The deal, expected to close in 1H 2025, gives Boston Scientific full control of Sonivie’s ultrasound-based Tivus system for renal denervation—an emerging hypertension treatment projected to be a billion-dollar market.

This isn’t Boston Scientific’s first rodeo. In the past year alone, the medtech giant has spent billions snapping up Axonics ($3.7B), Silk Road Medical ($1.28B), and Bolt Medical ($664M). Now, it's diving into the renal denervation space, following Medtronic and Recor Medical, whose devices recently won FDA approval.

With Medicare expected to expand coverage for the procedure, Boston Scientific is betting that Tivus’ ultrasound approach will carve out a piece of the action. If renal denervation takes off as analysts predict, this could be a high-stakes, high-reward play.

Love Healthcare150? Receive the Same Weekly Newsletter For the Private Equity Market!

PE150 delivers proprietary insights, market trends, and actionable tools for Private Equity & M&A professionals—in just one 5 minute weekly email. Subscribe now

The Healthcare Spending Chasm

Some gaps are big. Then there’s this: the U.S. spends 279x more per capita on healthcare than the Democratic Republic of Congo. The numbers? $9,729 per person in the U.S. vs. just $35 in the DRC. That’s not a gap—it’s a healthcare Grand Canyon.

The high rollers: The U.S. leads, followed by Monaco ($7,947), Switzerland ($7,280), Norway ($6,599), and Luxembourg ($6,034).

The underfunded: At the bottom, the DRC is trailed closely by South Sudan ($56), the Central African Republic ($56), Burundi ($61), and Niger ($61).

It’s a stark contrast that highlights inequalities in medical access, infrastructure, and public health investment.

"Don't let the fear of losing be greater than the excitement of winning"

Robert Kiyosaki